Drupal.behaviors.print = function(context) {window.print();window.close();}>
MDx/CDx Focus: Positive Data for Trastuzumab Emtansine; Veracyte Gets NY OK for Afirma Thyroid Dx
August 29, 2012
MDx/CDx Focus: Positive Data for Trastuzumab Emtansine; Veracyte Gets NY OK for Afirma Thyroid Dx
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Genentech Planning Regulatory Filing This Year for New Personalized Rx for Advanced Breast Cancer
June 6, 2012 / Pharmacogenomics Reporter
FDA Approves Genentech's Antibody-Drug Conjugate, Marking Third Rx for HER2-Targeted Breast Cancer
February 27, 2013 / Pharmacogenomics Reporter
During Investor Day, Roche Highlights Personalized Medicine as Key Area for Future Growth
September 12, 2012 / Pharmacogenomics Reporter
MDx/CDx Focus: Siemens Inks Companion Dx Partnerships; FDA Accepts Roche's Pertuzumab BLA
February 8, 2012 / Pharmacogenomics Reporter
Absent 'Gold Standard' for HER2 Testing, Researchers Question Role of Oncotype DX Beyond IHC/FISH
December 21, 2011 / Pharmacogenomics Reporter